Literature DB >> 28841231

Noncholestatic acute hepatocellular injury following candesartan administration.

Jan Antonio Lammel-Lindemann1,2, Eduardo Flores-Villalba1,2, Alexandro Jose Martagón2, Eduardo DeObeso-Gonzalez2, Francisco Puente-Gallegos2.   

Abstract

Arterial hypertension is a highly manageable disorder due to a variety of drugs available for its treatment. Since the late 1990s, angiotensin II receptor blockers have been widely prescribed, achieving appropriate control in patients' blood pressure. Few cases of serious adverse effects have been reported to date. Here, we present a case of acute hepatocellular injury secondary to candesartan administration. Further studies should be performed in patients who present with this adverse effect, in order to prevent more serious outcomes.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  Acute hepatitis; Angiotensin II antagonists; Candesartan

Mesh:

Substances:

Year:  2017        PMID: 28841231      PMCID: PMC5736849          DOI: 10.1111/bcp.13406

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  [Acute hepatitis induced by candesartan].

Authors:  I Vallejo; S García Morillo; E Pamies
Journal:  Med Clin (Barc)       Date:  2000-11-25       Impact factor: 1.725

2.  Candesartan and acute liver injury.

Authors:  D González-Jiménez; J M Varela; E Calderón; J Galindo; M A González de la Puente
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

3.  The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.

Authors:  Stephen Ph Alexander; Anthony P Davenport; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

4.  Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.

Authors:  Mara A McAdams; Laura A Governale; Lynette Swartz; Tarek A Hammad; Gerald J Dal Pan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-09       Impact factor: 2.890

5.  [Candesartan-induced cholestatic hepatitis: a case report].

Authors:  Manuel Jiménez-Sáenz; Quetzalihuitl Arroyo; Mileidis Sanjuan; Juan M Herrerías
Journal:  Gastroenterol Hepatol       Date:  2009-08-26       Impact factor: 2.102

6.  Candesartan cilexetil-induced severe hepatotoxicity.

Authors:  Giorgio Basile; Daniela Villari; Sebastiano Gangemi; Tiziana Ferrara; Maria G Accetta; Vittorio Nicita-Mauro
Journal:  J Clin Gastroenterol       Date:  2003-03       Impact factor: 3.062

7.  Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.

Authors:  P Sever; H Holzgreve
Journal:  J Hum Hypertens       Date:  1997-09       Impact factor: 3.012

Review 8.  Candesartan cilexetil. A review of its use in essential hypertension.

Authors:  K J McClellan; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 9.  RUCAM in Drug and Herb Induced Liver Injury: The Update.

Authors:  Gaby Danan; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971

  10 in total
  2 in total

Review 1.  Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.

Authors:  Rolf Teschke
Journal:  Front Pharmacol       Date:  2019-07-23       Impact factor: 5.810

2.  Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.

Authors:  Gyu Chul Oh; Kwon Wook Joo; Myung-A Kim; Dong-Ju Choi; Yoon Jun Kim; Hae-Young Lee
Journal:  Drug Des Devel Ther       Date:  2020-04-03       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.